Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for Hypercon technology.

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers.

Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash.

Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HCRx to support the planned launch of AD109.

As healthcare accelerates toward data intensive innovation, mounting pressure on hospital networks is exposing an uncomfortable truth: many are not ready.

In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...

Experts explore how leukapheresis is emerging as a critical chokepoint for both autologous and allogeneic cell therapies.

MSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer.

Aspect Biosystems has secured a $56.6m investment from the Government of Canada to support a C$280m multi-year project aimed at advancing its pipeline of bioengineered cellular medicines for endocrine ...

Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled ...

Otsuka Pharmaceutical is to fully acquire Transcend Therapeutics via its subsidiary Otsuka America for a potential ...